- Cell MedX (OTC: CMXC) is on track to file for FDA approval of their revolutionary eBalance device within the next 45 days.
- eBalance is on the market now, with more than 100 units already in the hands of customers.
- There are 30.1 million Americans with diabetes, 380 million worldwide means a vast, wide-open market.
It’s a public health crisis like few others – 9.4% of Americans have diabetes. And, the drug that keeps them alive – insulin – is made by just three multinational corporations.
In fact, Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), and Sanofi (NASDAQ:SNY) control 90% of the world’s insulin market.
Now, a young company has a novel breakthrough that could level the treatment playing field for diabetics. The company, Cell MedX (OTC: CMXC), has developed an instrument that treats diabetes at the cellular level by targeting the health of the malfunctioning beta cells that cause diabetes.
Cell MedX’s eBalance technology uses a spark to regenerate cells, much in the way nature does with animals, such as amphibians, which are able to regrow organs and limbs.
Like cracking the genetic code, the regeneration science behind Cell MedX’s technology is a true 21st century story. It’s another example of science fiction becoming reality.
Science Suggests Bioelectric Medicines Are The Wave Of The Future
Cell MedX is on the forefront of the “microcurrent” healthcare movement. Microcurrent is a therapy in which Cell MedX’s breakthrough eBalance technology sends a pulsating stream of electrons in relatively low concentrations throughout the body.
The eBalance device is noninvasive, and the electrical currents it delivers mimic the endogenous, or deep tissue, electric energy of the human body.
It’s “microcurrent” because eBalance uses a direct current of about 3 milliamperes.
And, because it sends micro currents deep into the body, eBalance is very different from electric pulse muscle stimulators, such as TENS.
That said, the muscle stimulation market could portend how huge a trend eBalance could become.
That’s because the global muscle stimulation is forecast to grow to $853 million during the next five years.
Microcurrents Are An Established Diabetes Therapy That Cell MedX Brings To The Next Level
The eBalance technology could take the market by storm because the success of basic microcurrent therapy is well documented and based upon years of research.
Since the 1980s, diabetic neuropathy and non-healing wounds have been successfully treated using programmed delivery of microcurrents.
Neuropathy is a side effect of diabetes. It’s when the brain misfires and causes tingling or severe pain in the hands and feet. It can be crippling.
But, it is its non-healing wounds that are the true scourge of diabetes.
That because most humans, over the course of a year, get a nick, or a scratch or a cut. But, diabetics’ high glucose levels suppress white blood cells’ healing power, and their power to destroy bacteria.
For them, bacterial infections can be brutal.
According to some reports, about 1 in 4 diabetics will suffer foot ulcers, which are painful sores that could ultimately lead to foot amputations.
In fact, the American Journal of Managed Care estimates there are about 230 amputations each day in the United States as a result of diabetes.
Cell MedX (OTC: CMXC) Is Getting Real Results In Real Trials With Real People
In an observational clinical trial, three months of eBalance treatments twice weekly caused no safety issues.
That’s important because even insulin therapy can be dangerous for diabetics. But the eBalance microcurrent treatments through its observational clinical trials demonstrated no harmful side effects.
More importantly, the trial revealed clear observational results:
After three months of bi-weekly eBalance treatments, the average fasting blood glucose levels in the trial’s diabetic subjects declined by 12.3%.
Their plasma insulin declined by 46.7%.
These results indicate that, on average, the blood glucose uptake was increased and that less insulin was required to achieve that uptake.
The next step should be a longer double-blind, placebo controlled study to see if greater effects are achieved with people who use the eBalance device over extended periods of time.
The Trial Revealed Other Superb Effects
While Cell MedX’s trial showed how it helps diabetics, researchers also observed other positive results from the eBalance therapy.
Those included these:
Blood pressure – After seven weeks of treatments, systolic pressure, the higher amount of pressure in the arteries during the contraction of the heart muscle, declined by 9.6%, and diastolic pressure, the lower pressure number in the arteries when the heart muscle is between beats, declined by 10.4%. A 10% decrease in blood pressure for individuals at risk from high blood pressure could be very beneficial without the side effects of medications.
Pain and numbness – Only two subjects reported suffering neuropathic pain at the beginning of the trial. Both reported feeling either less pain or reduced coldness or numbness in their extremities.
These findings support those of other trials. Cell MedX now would like to conduct further studies on neuropathy, and on other forms of chronic pain, such as gout, migraines, and inflammation.
Kidney function – Nephropathy and high blood pressure can prevent kidneys from functioning properly, or even causes them to fail completely. When the blood vessels in the kidneys are injured, the kidneys cannot clean the blood properly. The body will retain more water and salt than it should, which can result in weight gain and edema.
Among the trial’s observed results were indications that eBalance treatments improved kidney function, which is supported by individual observations of significant reductions of edema. A longer study on studies of kidney function could be in Cell MedX’s future.
These positive eBalance results, however, could be a gateway to the technology’s true promise.
That’s because, a 2010 clinical study found that microcurrents reversed a 74-year old woman’s diabetes and high blood pressure to the point where she no longer needed medication to control the diseases.
The results were published in the National Institute of Health’s U.S. National Library of Medicine.
Over and over and over again, the study reported a string of successes using microcurrents to get people healthy enough, so they no longer needed insulin to control their diabetes.
Cell MedX (OTC: CMXC) eBalance Technology Reinvigorates Injured Cells And Proteins
And, this is where Cell MedX’s eBalance technology separates itself from the pack and distinguishes itself as a potentially life-altering breakthrough.
Based on first-in-human observations, a specific set of bioelectric signals – of known waveform, frequency, amplitude, and duration – can be pulsed into the body to target beta cells and a protein known as glucose transporter type 4.
Beta cells make insulin, and it’s GLUT4 that transports insulin to the rest of the body when the beta cells tell it to.
Damaged beta cells contain damaged GLUT4.
In diabetics, when the body demands insulin it’s like trying to start a car that’s out of gas. Everything seems to be working, the radio is on, the lights work, the ignition works, but the car won’t start.
But, the breakthrough with eBalance is that it delivers the proper microcurrent to beta cells and GLUT4, so they release the insulin diabetics so desperately need.
eBalance Is On The Market Now
The U.S. Food And Drug Administration has yet to certify the claims Cell MedX makes about its breakthrough eBalance technology.
But, based on its trial’s success, Cell MedX has made its eBalance technology available today for people who hope to ease diabetes’ side effects, such as neuropathy and non-healing wounds.
And, it’s affordable. An eBalance unit can be leased for as little as $125 a month, which delivers 25 sessions. Currently, there more than 100 units in the hands of diabetics. So, Cell MedX has begun sit stagey for recurring revenue.
Moreover, a trip to the Cell MedX website reveals a host of thrilled testimonials.
That $125 a month, or $1,500 a year, is a bargain when measured against the economics of conventional treatments.
That’s because it can cost as much as $12,000 to have enough insulin on hand to treat a person with Type 1 diabetes.
As The Washington Post reported on June 16th, people such as a Minnesotan named Lija Greenwood make drug runs to Canada where insulin is 10 times less expensive as in the U.S.
Massive Cost Is Not A Surprise For People In The Know
The government knows how brutal insulin costs are. Between 2007 and 2017, total Medicare Part D spending on insulin increased 840%, from $1.4 billion to $13.3 billion.
Other interesting facts from the American Diabetes Association include:
- Total per-capita health expenditures for people with diabetes are higher among men than women – $10,060 a year vs. $9,110.
- Among states, California has the largest population with diabetes and thus the highest costs, at $39.47 billion. Texas ($25.60 billion), Florida ($24.80 billion), and New York ($21.23 billion) round out the top four states in terms of total annual cost.
- Research released March 22, 2018, estimated the total costs of diagnosed diabetes rose to $327 billion in 2017 from $245 billion in 2012, when the cost was last examined.
- The $327 billion broke down this way, $237 billion for direct medical cost, and $90 billion for reduced productivity.
Cell MedX Is Leading The Pack
Bioelectric medicine looks as if it’s going to be one of the 21st century’s top healthcare trends.
Grandview Research predicts that electroceutical/bioelectric medicine market will be a $35.5 billion by 2025.
That means Cell MedX (OTC: CMXC) could be seen as a leader in a field that includes:
GlaxoSmithKline (NYSE:GSK), which with support from Alphabet, set up Galvani Bioelectronics to work on an implant device that will wrap around a bundle of nerves to treat diseases.
Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT), both companies have a long history in bioelectronics with pacemakers and spinal cord stimulation devices.
Nevro Corp. (NASDAQ:NVRO), makes pain control devices using spinal cord stimulation.
The common theme with those companies are that their procedures are all invasive and all deal with pain management.
The difference is what makes Cell MedX a standout among its peers, because its eBalance technology aims to relieve the suffering from the millions of people worldwide for whom diabetes and its side effects is a debilitating force in their lives.
That Is Just One Of The 8 Reasons Why Cell MedX (OTC: CMXC) Could Turn Out To Be The Best Pure-Play In The Bioelectric Healthcare Field
Dramatic Results – Cell MedX’s eBalance technology greatly improves the lives of people with diabetes.
Huge Demand – The cost of insulin is prohibitive… 10s of thousands of dollars, even more than $100,000 or more over a lifetime.
Massive Potential – There is a chance that eBalance technology could rebalance the human body and fix the beta cells that cause diabetes.
Hundreds of Millions of Potential Users – There are about 380 million diabetics worldwide today. That is forecast to jump to 642 million by 2040.
Blood Pressure – More than 1 billion people worldwide have high blood pressure. Cell MedX, and other researchers, have found on both observational and clinical trials, that microcurrent therapy, such as offered by Cell MedX’s eBalance technology, can significantly lower blood pressure.
Recurring Revenue – Cell MedX leases devices with the eBalance technology by the month, with 20 treatments per month programmed into each device.
Tremendous Top Line – In a universe where diabetes patients are counted by the hundreds of millions, quickly leasing 10,000 eBalance units could make Cell MedX (CMXC) a $30 million company… 100,000 would make it a $300 million company.
Wild Card – Cell MedX is a one-of-a-kind company in a field dominated by major biotech corporations. But, they focus on pain management. The more success Cell MedX has with its eBalance technology, the greater the demand for it could be. That could greatly enhance the chances that Cell MedX could be acquired.
Today, Cell MedX (OTC: CMXC) is an early-stage bioelectric company with a high-potential technology.
It is exactly the kind of company aggressive tech investors dream of. Recent developments have already driven CMXC’s share price to nearly triple-digit gains in the past year. That makes Cell MedX a company to keep an eye on.
Learn More About CMXC at your brokerage today!
TheBullReport.com has been engaged to feature this report on behalf of Cell MedX Corp. This report is for information purposes only and is neither a solicitation nor recommendation to buy nor an offer to sell securities. TheBullReport.com is not-a-registered-investment-advisor. TheBullReport.com is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. TheBullReport.com accepts no liability for any losses arising from an investor’s reliance on the use of this material. TheBullReport.com sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. TheBullReport.com and its affiliates or officers currently hold no shares of these stocks. TheBullReport.com and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. TheBullReport.com will not update its purchases and sales of these stocks in any future postings on TheBullReport.com’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *TheBullReport.com does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment. Think Ink was engaged by and is acting on behalf of the issuer, CellMedX.